Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.

Vasileios K KavouridisKeith L LigonPatrick Y WenJ Bryan Iorgulescu

Published in: Journal of neuro-oncology (2022)

In a national analysis of gliosarcoma patients, temozolomide was associated with prolonged OS irrespective of MGMT status. These results provide support for the current practice of trimodal therapy for gliosarcoma.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
healthcare
prognostic factors
dna methylation
peritoneal dialysis
quality improvement